In a move long sought by innovation-driven industries, the new tax legislation known as the “One Big Beautiful Bill” will fully reinstate immediate expensing for domestic research and development (R&D) costs. Effective for tax years beginning after December 31, 2024, this change reverses the prior rule that required companies to amortize research and development (R&D) expenses over five years, which many business leaders argued stifled innovation and strained cash flow.
Under the restored provision, companies conducting qualifying R&D activities in the U.S. can now deduct the full cost in the year those expenses are incurred. This is expected to improve liquidity significantly and encourage continued or expanded investment in R&D projects.
Retroactive Relief for Small Businesses
Notably, the bill includes a retroactive provision allowing small businesses to apply these rules to tax years as far back as 2022. Business owners must act within one year of the bill’s enactment and file amended tax returns to claim the benefit. For smaller companies that invested heavily in R&D in recent years, this could result in meaningful refunds.
Foreign R&D Still Faces Limitations
While domestic R&D sees a boost, the legislation retains stricter treatment for foreign R&D activities. Expenses for overseas research must still be amortized over 15 years. This distinction may prompt some multinational firms to reconsider where they locate their research operations.
Wider Tax Shifts and Fiscal Impact
The bill also codifies several provisions from the 2017 Tax Cuts and Jobs Act, including the reduction of the corporate tax rate from 35% to 21% and an expanded standard deduction. It introduces new deductions for tipped and overtime workers, while eliminating various renewable energy tax credits, risking higher energy costs in certain sectors.
The Congressional Budget Office estimates the bill will add approximately $3.4 trillion to the national debt over the next decade. While supporters argue the legislation will stimulate economic growth, critics warn that rising deficits could trigger future cuts to Medicare, Medicaid, or other federally funded health programs.
How This Impacts Business Owners
For business owners, particularly those in innovation-heavy sectors, the restored R&D expensing rules offer several key benefits:
- Immediate Tax Savings: U.S.-based R&D expenses can now be fully deducted in the year they occur, improving cash flow and reducing tax burdens.
- Retroactive Refund Potential: Businesses that invested in R&D from 2022–2024 may amend prior returns to recover taxes paid under previous amortization rules.
- Incentive to Stay Domestic: Firms may shift more R&D activities back to the U.S. to maximize tax advantages.
Trade-Offs:
- Foreign Research Still Disadvantaged: R&D conducted abroad remains subject to a slower, 15-year amortization schedule.
- Administrative Complexity: Filing amended returns can be paperwork-intensive and may invite IRS scrutiny.
- Policy Stability Uncertain: With a major increase in national debt, some business leaders worry that future administrations may reverse the policy.
Impact on Healthcare Sectors
Pharmaceutical companies, biotech startups, and medical device manufacturers stand to benefit substantially. These firms typically invest heavily in R&D and will now enjoy faster write-offs and improved cash flow for ongoing innovation. Many people may now seek to amend past returns to recover taxes previously paid.
Smaller entities, like independent diagnostic labs or health tech developers, may also find new incentives to formalize or expand their R&D efforts. Clinics or practices developing proprietary software, treatment protocols, or medical tools may qualify for deductions under Section 174.
That said, traditional medical practices not engaged in experimental or product development activities are unlikely to benefit directly.
Patients: Innovation Gains, But No Cost Relief
Patients could indirectly benefit over time if increased R&D spending leads to faster development of new drugs, devices, or therapies. However, the bill does not contain provisions aimed at reducing healthcare costs, drug pricing, or insurance access. In fact, with simultaneous cuts to ACA subsidies and Medicaid funding, some patients may face higher out-of-pocket costs even as innovation accelerates.
Other Winners and Cautionary Notes
Additional beneficiaries include health tech startups, university research centers, and life sciences investors. Given the current areas of growth, these groups may be able to expect some valuation increases as tax savings are reinvested by R&D-intensive firms.
However, there are key caveats:
- Large Corporations Benefit Most: Bigger firms with large R&D budgets and tax resources will see the most advantage.
- Smaller Clinics May See No Impact: Providers not engaged in R&D will not benefit directly.
- Long-Term Fiscal Risks: The added debt could prompt future rollbacks or cuts elsewhere.
- Retroactive Claims Are Complex: Amending past returns will require documentation and professional tax support.
What Business Owners Should Do Now
If you’re a business owner in a healthcare-adjacent or innovation-focused field, consider taking the following steps:
- Consult your accountant or tax advisor to determine if your R&D activities qualify.
- Review your 2022–2024 tax returns to assess refund potential.
- Evaluate whether relocating R&D efforts to the U.S. could yield tax advantages.
- Ensure you maintain detailed, audit-ready documentation if claiming large deductions.
Medical Professionals: Don’t Overlook Potential Eligibility
Even small clinics or independent practices should evaluate whether any part of their operations, such as software development, new treatment protocols, or lab testing, meets the technical definition of R&D. If so, they may qualify for deductions they’ve never claimed before. This is especially important for smaller medical practices in rural areas, as medicaid funding cuts begin to affect such places first.
For Patients and Advocates
Stay informed. While these tax changes may help accelerate medical research, they do not lower the cost of care. Continue to advocate for broader reforms that keep innovation affordable and accessible.
Frequently Asked Questions: R&D Expensing Under the New Tax Law
Does my business qualify for immediate R&D expensing?
If your company develops or improves products, processes, software, or technologies in the U.S., you may qualify. Yet this isn’t limited to tech or pharmaceutical companies, as there are many industries engaging in R&D without realizing it.
What counts as R&D under Section 174?
Qualifying activities typically include product development, software design, process improvement, and technical experimentation. Routine updates or changes made after commercial release do not qualify.
Can I deduct R&D costs from 2022–2024?
Yes. The law allows retroactive expensing back to 2022. Smaller businesses, generally those with average gross receipts under $29–31 million, can file amended returns for refunds. Larger companies may deduct remaining unamortized costs over 2025–2026.
Will amending returns raise audit risk?
Amended returns receive more scrutiny. Work with a qualified tax advisor and ensure all claims are well-supported.
I do R&D overseas. Does this help me?
No. Foreign R&D must still be amortized over 15 years. Some companies may consider moving those activities back to the U.S.
I’m a medical professional. Will this apply to me?
Possibly. Independent labs or practices investing in new platforms, procedures, or technology may qualify. It’s worth reviewing with a healthcare-savvy tax advisor.
Will this lower drug prices or healthcare costs?
Not directly. While faster innovation may benefit patients over time, the bill does not address cost controls or access.
Should I shift more R&D into 2025 and beyond?
Likely yes, to take full advantage of immediate expensing. But always consult your advisor before making timing decisions.
What’s the deadline for retroactive expensing?
Amended returns must be filed within one year of the bill’s enactment. Don’t wait.
Do state taxes conform to this change?
Not all states conform. Check with your accountant on state-specific rules.
Will the IRS issue guidance?
Yes. Formal guidance is expected on election procedures and documentation. Stay updated through your tax professional.
What’s my next step?
Meet with your accountant or tax advisor to assess eligibility, explore amended return opportunities, and implement documentation practices going forward.
